HPSE in Ocular Herpes Infection

HPSE 在眼部疱疹感染中的应用

基本信息

  • 批准号:
    9761531
  • 负责人:
  • 金额:
    $ 39.98万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-01 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

The major clinical complications associated with herpes simplex virus -1 (HSV-1) infection of the eye include corneal ulcers, severe pain, inflammation, loss of corneal avascularity, and vision loss. Antiviral agents alone often fail to correct the problems because many of the disease symptoms may be signaled by infection but then regulated more directly by host molecules. This proposal studies, human heparanase (HPSE), a host enzyme that may potentially regulate both, virus growth and disease manifestations in the cornea. HPSE is a heparan sulfate (HS) endoglycosidase whose levels correlate directly with the breakdown of epithelial and endothelial basement membrane barriers, increased vascular permeability and leukocyte extravasation, and liberation of HS-bound cytokines and growth factors promoting angiogenesis and inflammation in the surrounding areas. The PI’s laboratory has recently observed a significant increase in HPSE expression and higher enzymatic activity upon HSV infection of human corneal cells, cultured human corneas, and animal models of ocular infection and demonstrated its significance in viral spread and transmission. In murine corneas HPSE upregulation directly contributes to corneal disease pathologies including ulceration, inflammation and neovascularization. In addition, we unexpectedly found that HPSE knockout cells show a severe deficiency in virus production. Therefore, based on our newly generated preliminary results we hypothesize an important regulatory role for HPSE in HSV-1 transcription and propose to establish HPSE as a key host virulence factor. We propose that activated HPSE directly adds to the severity of herpetic diseases including tissue damage and promotes viral infection and reactivation. This proposal will focus on understanding the HPSE driven mechanisms that contribute to HSV-1 growth in the cornea and demonstrating the antiviral/anti-inflammatory effects of HPSE inhibition or chromosomal deletion. Three Aims are proposed. First Aim will establish the molecular basis behind the loss of HSV-1 infection in cells lacking HPSE. It is based on our hypothesis that HPSE through its nuclear localization and complex set of interactions promote HSV-1 transcription. Second Aim will determine the significance of HPSE in HSV-1 infection of the murine cornea. This Aim will use a HPSE knockout mouse model to prove our hypothesis that HPSE is a host virulence factor that promotes HSV-1 infection in the cornea, drives tissue damage and disease pathologies, and facilitates viral spread to and return from the trigeminal ganglia (TG) during reactivation. The third and final Aim will determine the therapeutic benefits of an HPSE inhibitor against HSV-1 infection of the cornea. This Aim will prove our hypothesis that pharmacological inhibition of HPSE will result in unprecedented therapeutic benefits including quick resolution of infection and corneal inflammation. Successful conclusion of our study will help establish a brand new role for HPSE as a host virulence factor and identify new factors that help promote its pathogenic activities in the cornea. Our results will significantly enhance our understanding of HPSE functions and herpetic disease mechanisms, and accelerate new strategies to control ocular infection.
与眼睛的单纯疱疹病毒-1(HSV -1)感染有关的主要临床并发症包括 角膜溃疡,严重的疼痛,炎症,角膜丧失和视力丧失 通常无法纠正问题 然后由宿主分子更直接地调节。 可能调节角膜中病毒生长和疾病表现的酶。 硫酸乙酰肝素(HS)内糖苷酶,其水平与上皮分解直接相关 室内地下室膜屏障,血管渗透性增加和白细胞渗出,并 解放了HS结合的细胞因子和增长因子促进子的启动子和炎症 周围地区。 人角膜细胞,培养的人角膜和动物的HSV感染后,酶活性较高 眼部感染的模型表现出其在病毒传播中的重要性 角膜HPSE上调直接有助于角膜疾病病理,包括溃疡, 炎症和新生血管化。 因此,基于新生成的预赛,病毒的严重缺乏 假设HPSE在HSV-1转录中扮演重要的规律性角色,并建议将HPSE建立为 我们提出的一个关键宿主病毒因素直接激活HPSE 包含组织损伤并促进病毒感染和重新激活。 了解HPSE驱动的机制,这些机制有助于角膜中HSV-1的增长 证明了抑制或染色体缺失的抗抗血液/抗炎作用。 目的是支撑的。 缺乏HPSE。 相互作用促进HSV-1转录。 鼠角膜的感染。 HPSE是一种宿主病毒因子,它在角膜中感染HSV-1,驱动组织损伤和 疾病的病理,并促进病毒传播到三叉神经节(TG)期间的病毒传播 重新激活。 角膜的HSV-1感染。 将带来前所未有的治疗益处,包括快速解决感染和角膜 炎症。 病毒因素并确定有助于促进其角膜的致病活性的新因素。 将大大增强我们对HPSE功能和疱疹疾病机制的理解,并 加速控制眼部感染的新策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DEEPAK SHUKLA其他文献

DEEPAK SHUKLA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DEEPAK SHUKLA', 18)}}的其他基金

HPSE in Ocular Herpes Infection
HPSE 在眼部疱疹感染中的应用
  • 批准号:
    10242774
  • 财政年份:
    2018
  • 资助金额:
    $ 39.98万
  • 项目类别:
HPSE in Ocular Herpes Infection
HPSE 在眼部疱疹感染中的应用
  • 批准号:
    10475706
  • 财政年份:
    2018
  • 资助金额:
    $ 39.98万
  • 项目类别:
A small molecule inhibitor of HSV genital infections
HSV 生殖器感染的小分子抑制剂
  • 批准号:
    10205994
  • 财政年份:
    2018
  • 资助金额:
    $ 39.98万
  • 项目类别:
A small molecule inhibitor of HSV genital infections
HSV 生殖器感染的小分子抑制剂
  • 批准号:
    9763444
  • 财政年份:
    2018
  • 资助金额:
    $ 39.98万
  • 项目类别:
HPSE in Ocular Herpes Infection
HPSE 在眼部疱疹感染中的应用
  • 批准号:
    10753834
  • 财政年份:
    2018
  • 资助金额:
    $ 39.98万
  • 项目类别:
A new molecular therapy against ocular herpes
一种针对眼部疱疹的新分子疗法
  • 批准号:
    10557908
  • 财政年份:
    2015
  • 资助金额:
    $ 39.98万
  • 项目类别:
A new molecular therapy against ocular herpes
一种针对眼部疱疹的新分子疗法
  • 批准号:
    8962978
  • 财政年份:
    2015
  • 资助金额:
    $ 39.98万
  • 项目类别:
A new molecular therapy against ocular herpes
一种针对眼部疱疹的新分子疗法
  • 批准号:
    9313256
  • 财政年份:
    2015
  • 资助金额:
    $ 39.98万
  • 项目类别:
A new molecular therapy against ocular herpes
一种针对眼部疱疹的新分子疗法
  • 批准号:
    10363614
  • 财政年份:
    2015
  • 资助金额:
    $ 39.98万
  • 项目类别:
Novel Peptides Against Modified Heparan Sulfate
抗修饰硫酸乙酰肝素的新肽
  • 批准号:
    8917086
  • 财政年份:
    2014
  • 资助金额:
    $ 39.98万
  • 项目类别:

相似国自然基金

髋关节撞击综合征过度运动及机械刺激动物模型建立与相关致病机制研究
  • 批准号:
    82372496
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目
基于中医经典名方干预效应差异的非酒精性脂肪性肝病动物模型证候判别研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    53 万元
  • 项目类别:
    面上项目
利用肝癌动物模型开展化学可控的在体基因编辑体系的研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    54 万元
  • 项目类别:
    面上项目
雌激素抑制髓系白血病动物模型中粒细胞异常增生的机制
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目
无菌动物模型与单细胞拉曼技术结合的猴与人自闭症靶标菌筛选及其机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Nanoparticle-mediated targeting of hepatic macrophages to mitigate inflammation in alcoholic liver disease
纳米颗粒介导的肝巨噬细胞靶向减轻酒精性肝病炎症
  • 批准号:
    10352578
  • 财政年份:
    2022
  • 资助金额:
    $ 39.98万
  • 项目类别:
Therapeutic implications of purinergic receptor P2X4 in ischemic stroke
嘌呤能受体 P2X4 在缺血性中风中的治疗意义
  • 批准号:
    10634727
  • 财政年份:
    2022
  • 资助金额:
    $ 39.98万
  • 项目类别:
Antihypertensive Effect of Food-Origin Isothiocyanate Soluble Epoxide Hydrolase Inhibitors
食品源异硫氰酸酯可溶性环氧化物水解酶抑制剂的抗高血压作用
  • 批准号:
    10411131
  • 财政年份:
    2022
  • 资助金额:
    $ 39.98万
  • 项目类别:
Effect of a semi-synthetic oxysterol drug candidate, Oxy210, on atherosclerosis in a mouse model of NASH
半合成氧甾醇候选药物 Oxy210 对 NASH 小鼠模型动脉粥样硬化的影响
  • 批准号:
    10474926
  • 财政年份:
    2022
  • 资助金额:
    $ 39.98万
  • 项目类别:
Antihypertensive Effect of Food-Origin Isothiocyanate Soluble Epoxide Hydrolase Inhibitors
食品源异硫氰酸酯可溶性环氧化物水解酶抑制剂的抗高血压作用
  • 批准号:
    10706992
  • 财政年份:
    2022
  • 资助金额:
    $ 39.98万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了